| Substance | Condition | Seq | Src | PMID | Dtl | Title |
| UDCA | Cholestasis | 3 | PM | 38244730 | 📋 | Ursodeoxycholic acid and 18β-glycyrrhetinic acid alleviate ethinylestradiol-induced cholestasis via downregulating RORγt and CXCR3 signaling pathway in iNKT cells |
| UDCA | Cholestasis | 1 | PM | 31077342 | 📋 | Ursodeoxycholic acid accelerates bile acid enterohepatic circulation |
| UDCA | Cholestasis | 2 | PM | 23722250 | 📋 | Ursodeoxycholic acid stabilizes the bile salt export pump in the apical membrane in MDCK II cells |
| UDCA | Hepatic Cirrhosis | 1 | PM | 23592128 | 📋 | Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial |
| UDCA | Hepatotoxicity | 4 | PM | 38395998 | 📋 | Ameliorative effect and mechanism of ursodeoxycholic acid on hydrogen peroxide-induced hepatocyte injury |
| UDCA | Hepatotoxicity | 2 | PM | 37381715 | 📋 | Protective effect of ursodeoxycholic acid and resveratrol against tacrolimus induced hepatotoxicity |
| UDCA | Hepatotoxicity | 1 | PM | 34483625 | 📋 | Comparing the Protective Effects of Curcumin and Ursodeoxycholic Acid after Ethanol-Induced Hepatotoxicity in Rat Liver |
| UDCA | Hepatotoxicity | 3 | PM | 23160382 | 📋 | The protective role of pomegranate juice against carbon tetrachloride-induced oxidative stress in rats |
| UDCA | Hyperbilirubinemia | 1 | PM | 38085723 | 📋 | Evaluation of therapeutic effect of oral Ursodeoxycholic Acid on indirect hyperbilirubinemia in term neonates undergoing phototherapy: A randomized controlled clinical trial |
| UDCA | Liver Cancer | 2 | PM | 38325224 | 📋 | Bile acids mediate fructose-associated liver tumour growth in mice |
| UDCA | Liver Cancer | 1 | PM | 19728331 | 📋 | Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma |
| UDCA | Liver Damage | 2 | PM | 38578526 | 📋 | Ursodeoxycholic and chenodeoxycholic bile acids attenuate systemic and liver inflammation induced by lipopolysaccharide in rats |
| UDCA | Liver Damage | 1 | PM | 38378025 | 📋 | UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis |
| UDCA | Liver Disease | 1 | PM | 31236688 | 📋 | UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications |
| UDCA | MAFLD | 3 | PM | 38576492 | 📋 | Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives |
| UDCA | MAFLD | 2 | PM | 38344336 | 📋 | The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review |
| UDCA | MAFLD | 1 | PM | 38158979 | 📋 | [Possibilities for the use of ursodeoxycholic acid in the treatment of patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease] |
| UDCA | Non-Alcoholic Steatohepatitis | 2 | PM | 38643542 | 📋 | A high-dose of ursodeoxycholic acid treatment alleviates liver inflammation by remodeling gut microbiota and bile acid profile in a mouse model of non-alcoholic steatohepatitis |
| UDCA | Non-Alcoholic Steatohepatitis | 1 | PM | 24053454 | 📋 | The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review |
| UDCA | Primary Biliary Cholangitis | 2 | PM | 37978445 | 📋 | High neutrophil-lymphocyte ratio indicates a worse response to ursodeoxycholic acid in primary biliary cholangitis: a retrospective cohort study |
| UDCA | Primary Biliary Cholangitis | 1 | PM | 27893675 | 📋 | A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis |
